- Home
- IVCA vs ADAG Comparison
IVCA vs ADAG Comparison
Compare IVCA & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVCA
- ADAG
- Stock Information
- Founded
- IVCA 2021
- ADAG 2011
- Country
- IVCA Cayman Islands
- ADAG China
- Employees
- IVCA N/A
- ADAG N/A
- Industry
- IVCA Blank Checks
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- IVCA Finance
- ADAG Health Care
- Exchange
- IVCA Nasdaq
- ADAG Nasdaq
- Market Cap
- IVCA 93.8M
- ADAG 85.9M
- IPO Year
- IVCA 2022
- ADAG 2021
- Fundamental
- Price
- IVCA $11.85
- ADAG $1.84
- Analyst Decision
- IVCA
- ADAG Strong Buy
- Analyst Count
- IVCA 0
- ADAG 1
- Target Price
- IVCA N/A
- ADAG $5.00
- AVG Volume (30 Days)
- IVCA 3.2K
- ADAG 24.0K
- Earning Date
- IVCA 01-01-0001
- ADAG 03-09-2025
- Dividend Yield
- IVCA N/A
- ADAG N/A
- EPS Growth
- IVCA N/A
- ADAG N/A
- EPS
- IVCA 0.26
- ADAG N/A
- Revenue
- IVCA N/A
- ADAG $815,746.00
- Revenue This Year
- IVCA N/A
- ADAG N/A
- Revenue Next Year
- IVCA N/A
- ADAG $2.70
- P/E Ratio
- IVCA $45.99
- ADAG N/A
- Revenue Growth
- IVCA N/A
- ADAG N/A
- 52 Week Low
- IVCA $11.06
- ADAG $1.74
- 52 Week High
- IVCA $12.37
- ADAG $4.38
- Technical
- Relative Strength Index (RSI)
- IVCA 54.79
- ADAG 40.33
- Support Level
- IVCA $11.76
- ADAG $1.76
- Resistance Level
- IVCA $12.03
- ADAG $2.07
- Average True Range (ATR)
- IVCA 0.05
- ADAG 0.14
- MACD
- IVCA 0.01
- ADAG -0.00
- Stochastic Oscillator
- IVCA 33.33
- ADAG 23.53
About IVCA Investcorp India Acquisition Corp.
Investcorp AI Acquisition Corp is a blank check company.
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.